Quarter
Charts
πŸ‡ΊπŸ‡ΈUS Markets

CARIS LIFE SCIENCES, INC.

CAI

CIK 0002019410 Β· Quarterly mode Β· latest period FY2025 (Q4) (ending 2025-12-31) Β· sourced from SEC EDGAR

At a glance Β· FY2025 (Q4)

Revenue
$293M
↑+125.4% +$163Mvs FY2024 (Q4)
Operating Income
$12M
↓-86.7% -$81Mvs FY2024 (Q4)
Net Income
$1M
↓-98.6% -$79Mvs FY2024 (Q4)
Gross Profit
$293M
↑+125.4% +$163Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot Β· latest annual filed values Β· S&P 500 calibration

Strong
69/100
  • Profitability
    0ROIC 3.9% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 7.85 (above 1.5 = solid)
  • Leverage
    67D/E 0.66 (under 0.5 = conservative)
  • Efficiency
    44Asset Turnover 0.77x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +188.2% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 4.3% Β· trend +66.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project CAI's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≀ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$6.88
Total enterprise IV
$1.15B
Diluted shares
0.17B
Terminal PV
$834M (72% of total)
Year-5 FCF
$98M
YearProjected FCFDiscounted PV
+1$72M$66M
+2$78M$64M
+3$84M$63M
+4$91M$62M
+5$98M$61M
Terminal$1.34B$834M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target β€” and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation Β· trailing 4 quarters

how the company spent its cash
Capex (TTM)
$14M
investment in PP&E
Stock buybacks (TTM)
$113K
share count reduction
Stock-based comp (TTM)
$61M
non-cash dilution

Balance sheet Β· 2025-12-31

latest filed snapshot
Total assets
$1.13B
everything owned
Total liabilities
$548M
everything owed
Stockholders' equity
$577M
shareholder claim
Net debt
$-418M
Net cash position ($418M)

Recent performance Β· 6 quarters

Revenue↑+188.2% +$191M
$293M
Net Income↑+136.8% +$91M
$24M
Free Cash Flow↑+2271.2% +$42M
$40M
Operating Margin↑+64.1pts
4.3%

Drill down